MRSA drug dosage calculations found to be inaccurate for children over 10

The emergence of MRSA (Staphylococcus aureus), dubbed a 'superbug' due to its resistance to many antibiotic drugs, has resulted in the glycopeptide antibiotic Vancomycin being commonly prescribed for patients in hospital.

However, MRSA's resistance to drugs has led to concerns of a 'creeping minimum' in the concentration of the dosage required to treat infection. In , nomograms are used to calculate the correct dosage of Vancomycin based on a patient's weight and creatinine levels.

While these adult nomograms are widely thought to be suitable for teenagers, pharmacological differences between teens and young adults remain poorly understood.

New research, published in the Journal of Clinical Pharmacology, explores the accuracy of adult nomograms in children over ten. The results of 120 patients from a children's' hospital in Vanderbilt, Nashville, revealed that Vancomycin nomograms from adults were not accurate in predicting appropriate dosing levels in .

"Based on the variability of pharmacokinetic parameters and drug clearance, the two Vancomycin nomograms developed to predict therapeutic Vancomycin concentrations in healthy adults did not accurately estimate dosage regimens in older children regardless of weight or age, and therefore should not be used to aid empiric dosing," said Dr. Jessica Gillon. "Further prospective studies are warranted for teens between 10 and 18 years of age to determine the most appropriate Vancomycin dosing to maximize drug efficacy and reduce the risk of Vancomycin induced renal toxicity."

More information: Jessica E. Gillon, James E. Cassat, M. Cecilia Di Pentima, 'Validation of two vancomycin nomograms in patients 10 years of age and older' The Journal of Clinical Pharmacology, Wiley, DOI: 10.1002/jcph.173

add to favorites email to friend print save as pdf

Related Stories

Less commonly prescribed antibiotic may be better

Aug 16, 2012

The antibiotic most commonly prescribed to treat bloodstream infections in dialysis patients may not always be the best choice, according to a study appearing in an upcoming issue of the Journal of the American Society of ...

Vibativ approved for certain bacterial pneumonia

Jun 24, 2013

(HealthDay)—The antibiotic Vibativ (telavancin) has been approved by the U.S. Food and Drug Administration to treat pneumonia caused by Staphylococcus aureus bacteria when other treatments aren't suitable.

Recommended for you

Expression of privilege in vaccine refusal

21 hours ago

Not all students returning to school this month will be up to date on their vaccinations. A new study conducted by Jennifer Reich, a researcher at the University of Colorado Denver, shows that the reasons why children may ...

Using computers to design drugs

Aug 22, 2014

Designing a new medicine is an expensive and time consuming business. Typically it takes around $2 billion and ten years for a new drug to move from its initial design in the lab, to the clinic. All the ...

User comments